ArticleJournal of oral biology and craniofacial research
Phytochemicals profile, cellular viabillity and platelet activity of
Article in Journal of oral biology and craniofacial research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Natural polymers in diabetes management: formulation prospects ofFrontiers in bioengineering and biotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: to investigates the phytochemical content of Methods: The cytotoxicity of the leaf extract was evaluated using fibroblast cells, with various concentrations of the extract. The platelet activity of the HrsL, was assessed by treating blood and analysing the concentration of P-selectin and platelet aggregation with the agonists epinephrine, ADP, and collagen, compared to blood without extract treatment as a control. Results: The Conclusion: HrsL non-toxic at low concentrations and increases platelet P-selectin, It does not decrease platelet aggregation with the epinephrine agonist at 7.8 mg/mL, but it reduces aggregation at concentrations above 7.8 mg/mL. It does not decrease platelet aggregation with the ADP and collagen agonists at concentrations less than or equal to 62.5 mg/mL, but reduces aggregation at concentrations above 62.5 mg/mL.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.